The immunosuppressive tumor microenvironment in triple-negative breast cancer could hinder the response to thorough immunotherapy and diminish the antitumor efficacy. Although the STING pathway emerges as a promising target to remedy defects, uncertain drug delivery might lead to off-target inflammatory reactions. Here, we manifest a novel phototheranostic agent with an aggregation-induced emission property that guided the pharmacological activation of a STING agonist for photothermal immunotherapy to create an immunologically "hot" tumor. A pyridinium rotor strategy is proposed to develop a positively charged TBTP-Bz, which is stably coincorporated with a STING agonist MSA-2 into thermal-responsive exosome-liposome hybrid nanoparticles for tumor-targeting delivery. TBTP-Bz exhibits aggregation-enhanced NIR-II emission and a photoacoustic signal, accomplishing real-time tumor tracking. Its photothermal stimulation induces immunogenic cancer cell death and promotes the precise release of MSA-2, thus boosting STING activation and STING-mediated type I interferon production. Significantly, single-dose photoimmunotherapy effectively suppresses abscopal tumor growth and provokes an immune memory effect to inhibit postsurgical recurrent and rechallenged tumors. This demonstrates promising clinical potential for poorly immunogenic breast cancer.
Ultrahigh dose-rate (FLASH) radiotherapy is an emerging technology with excellent therapeutic effects and low biological toxicity. However, tumor recurrence largely impede the effectiveness of FLASH therapy. Overcoming tumor recurrence is crucial for practical FLASH applications. Here, we prepared an agarose-based thermosensitive hydrogel containing a mild photothermal agent (TPE-BBT) and a glutaminase inhibitor (CB-839). Within nanoparticles, TPE-BBT exhibits aggregation-induced emission peaked at 900 nm, while the unrestricted molecular motions endow TPE-BBT with a mild photothermy generation ability. The balanced photothermal effect and photoluminescence are ideal for phototheranostics. Upon 660-nm laser irradiation, the temperature-rising effect softens and hydrolyzes the hydrogel to release TPE-BBT and CB-839 into the tumor site for concurrent mild photothermal therapy and chemotherapy, jointly inhibiting homologous recombination repair of DNA. The enhanced FLASH radiotherapy efficiently kills the tumor tissue without recurrence and obvious systematic toxicity. This work deciphers the unrestricted molecular motions in bright organic fluorophores as a source of photothermy, and provides novel recurrence-resistant radiotherapy without adverse side effects.
Organic dyes with photoluminescence in the second near-infrared window (NIR-II, 1000–1700 nm) are essential in bioimaging and optoelectronic devices. Photoluminescence quantum yield (PLQY) is their important performance indicator. Integrating sphere technology is effective in determining the absolute PLQY. However, the low emission brightness of most NIR-II organic fluorophores results in unacceptable errors. Therefore, the most common method for determining the PLQY is a relative approach using photoluminescence spectrometers and a standard reference like IR-26. Although the relative method can obtain accurate PLQY ratios between the samples and references, the specific PLQY value of IR-26 is not clearly defined, which is reported to range from 0.05% to 0.50%. Such a deviation can cause significant errors in relative PLQY measurements. In this study, a bright organic fluorophore called TPE-BBT exhibits a high PLQY of 4.17% in THF, which can be accurately measured using a commercially available integrating sphere. Using TPE-BBT as a standard reference, we have determined the PLQY values of IR-26 in DCE to be 0.0301% and IR-1061 in DCM to be 0.193%.
5 October 2026 in Journal of the American Chemical Society